Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have been assigned a consensus recommendation of “Buy” from the thirteen analysts that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $31.13.

HRTX has been the topic of several analyst reports. Mizuho reissued a “buy” rating and set a $28.00 target price on shares of Heron Therapeutics in a report on Tuesday, November 7th. Cowen reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a research note on Monday, November 6th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Heron Therapeutics in a research note on Thursday, November 2nd. Oppenheimer assumed coverage on Heron Therapeutics in a research note on Monday, October 30th. They issued a “buy” rating and a $27.00 price objective on the stock. Finally, Noble Financial reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Heron Therapeutics in a research note on Friday, October 6th.

In related news, VP Kimberly Manhard sold 7,584 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total value of $151,680.00. Following the sale, the vice president now directly owns 7,584 shares of the company’s stock, valued at $151,680. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 19.93% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. Parametric Portfolio Associates LLC raised its position in Heron Therapeutics by 2.3% in the second quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock valued at $470,000 after purchasing an additional 771 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in Heron Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock valued at $2,363,000 after purchasing an additional 1,026 shares during the last quarter. HighTower Advisors LLC raised its position in Heron Therapeutics by 11.4% in the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 1,700 shares during the last quarter. Tudor Investment Corp ET AL raised its position in Heron Therapeutics by 10.2% in the second quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock valued at $258,000 after purchasing an additional 1,724 shares during the last quarter. Finally, Legal & General Group Plc raised its position in Heron Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 2,383 shares during the last quarter. Hedge funds and other institutional investors own 98.21% of the company’s stock.

Heron Therapeutics (NASDAQ:HRTX) traded up $0.30 on Friday, hitting $23.20. The stock had a trading volume of 935,200 shares, compared to its average volume of 1,120,538. The firm has a market cap of $1,270.00, a price-to-earnings ratio of -6.12 and a beta of 2.12. Heron Therapeutics has a 12 month low of $12.25 and a 12 month high of $23.35. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.10. The company had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. equities analysts anticipate that Heron Therapeutics will post -3.38 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2018/01/22/brokerages-set-heron-therapeutics-inc-hrtx-price-target-at-31-13.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.